Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Indiana University
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07640139CT.gov Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | — | Enrolling By Invitation | — | — | — |
NCT07042672CT.gov Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity | — | Recruiting | — | — | — |
NCT07368855CT.gov GLP-1 Medicines and Mental Health Changes | — | Completed | — | — | — |
NCT03414333CT.gov To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity. | — | Completed | — | — | — |
NCT01880827CT.gov Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery | — | Completed | — | — | — |
NCT01677104CT.gov The Microvascular Function of GLP-1 and Its Analogues | — | Completed | — | — | — |
NCT00940134CT.gov Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Glucagon-Like Peptide 1, Human (this asset) | Indiana University | P1 | C · 39 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Glucagon-Like Peptide 1, Human
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | P2 | CCC · 53 |
| Type 2 Diabetes Mellitus | — | P1 | CC · 42 |
| Depressive Disorder | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Glucagon-Like Peptide 1, Human in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/glucagon-like-peptide-1-human-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →